On Friday, Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) released topline results from the Phase 3 trial of the combined mRNA vaccine candidate against influenza and COVID-19 in healthy ...

In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectivesThe trial did not meet one of its ...

FluMist is the only nasal flu vaccine, but it is not new. The FDA approved it in 2003 for people 5 to 49 years old before ...

The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...

The revamped vaccine is an effort by regulators and vaccine makers to keep pace with the virus, which continues to evolve ...

Discover the significant differences in influenza and COVID-19 vaccination rates among children receiving long-term ...

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and older Data demonstrate that the Omicron KP.2-adapted ...

Epidemiologists and a federal health agency have criticized new COVID-19 guidance from Florida Surgeon General Joseph Ladapo ...

“BioNTech”) today announced top-line results from their Phase 3 clinical trial to evaluate the companies’ combined mRNA vaccine candidate against influenza and COVID-19 in healthy ...